We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial

News   Feb 01, 2012

 
Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial
 
 
 

RELATED ARTICLES

“Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer

News

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers.

READ MORE

Paradigm Shift for Design of Universal Vaccines

News

Killer T cells have been identified that can fight all influenza viruses – A, B and C – creating the potential for the development of a world-first universal, one-shot flu vaccine.

READ MORE

Machine Learning Swiftly Analyzes Nanomedicines for Cancer Immunotherapy

News

With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE